CPHI Milan 2026: How the Pharmaceutical Industry Is Evolving

CPHI 2026 in Milan offered an opportunity to assess the direction of the pharmaceutical industry and explore the technologies, products and partnerships that will shape its future.

As Business Development Director at Sona Group, I approached the exhibition with a focus on practical value: the scientific foundation behind new products, the needs they address and their potential for successful market entry.

My main takeaway from Milan is that competitive advantage increasingly depends on a company’s ability to combine scientific expertise, technology, manufacturing quality and market understanding with effective partnerships.

Innovation Must Address a Specific Need

Innovation has become a familiar term in pharmaceutical presentations. For me, its real value lies in what it improves for patients, healthcare professionals or healthcare systems.

A new molecule may create new treatment opportunities, but meaningful progress can also come from more convenient dosage forms, improved product stability or simpler administration.

When evaluating new developments, I focus on their readiness for practical implementation. What research has been completed? Can consistent quality be achieved at an industrial scale? What regulatory requirements remain, and how will the product reach its market?

These questions help distinguish promising concepts from commercially viable products. Uncertainty in development, documentation or manufacturing can affect launch timelines, investment and professional confidence.

The most convincing innovations are therefore those supported by scientific evidence and a clear implementation strategy.

New Dosage Forms: Improving the Patient Experience

Drug delivery systems, finished dosage forms and packaging were among the important areas represented at CPHI 2026.

Their development addresses a practical question: how can treatment become more convenient and manageable in everyday life?

Clear instructions, accurate dosing and ease of administration are particularly important for children, older adults and patients receiving long-term treatment.

From a business development perspective, these improvements must offer measurable benefits at a reasonable cost. Their value depends on patient needs, supporting evidence and the impact on product affordability.

For me, one of the most important achievements of pharmaceutical technology is its ability to make treatment simpler and more convenient for patients.

Biomanufacturing: Opportunities and Infrastructure

Biomanufacturing demonstrates how closely scientific development is connected to manufacturing capabilities.

When assessing biological medicines and biosimilars, I consider the entire system supporting the product, including process reproducibility, quality control, analytical capabilities, storage, transportation and post-launch support.

Commercial potential must also be evaluated within the local healthcare system. Reimbursement mechanisms, procurement practices, treatment decisions and patient access all influence market opportunities.

Technological potential and market readiness must be assessed together to identify sustainable opportunities for development.

Digital Technologies: From Ideas to Measurable Results

The AI & Tech segment at CPHI 2026 reflects the growing role of digital solutions in pharmaceuticals.

I see their potential in specific applications such as data analysis, production planning, documentation management, demand forecasting and process monitoring.

However, the effectiveness of these tools depends on data quality, reliability and clearly defined responsibility for results.

In pharmaceuticals, speed must be accompanied by accuracy and traceability. Digital technologies should integrate into existing processes and support better-informed professional decisions.

Supply Reliability as Part of Product Value

Evaluating a pharmaceutical partnership goes beyond product quality and competitive pricing. Manufacturing capacity, delivery schedules, demand forecasting and communication are equally important.

A reliable partner must be able to maintain consistent supply, communicate potential changes in advance and address challenges collaboratively.

An attractive commercial proposal may generate interest at an exhibition, but a reliable business model determines whether commitments can be fulfilled over time.

Ultimately, supply reliability has a direct impact on patients whose treatment depends on the availability of medicines.

Sustainability: Practical Decisions and Responsibility

The Sustainability Summit at CPHI 2026 highlighted the industry’s focus on responsible development.

For me, sustainability is most meaningful when reflected in practical decisions concerning energy and water consumption, waste management, supplier evaluation, packaging and logistics.

Every improvement must maintain product quality, patient safety and regulatory compliance. This requires investment, technical expertise and a consistent approach.

A company’s maturity is demonstrated by its ability to support such decisions with measurable results and consider their long-term consequences.

Market Entry: The Importance of Local Expertise

As Business Development Director, I pay particular attention to transforming international opportunities into successful local projects.

The same pharmaceutical product may require different strategies across markets due to regulatory requirements, purchasing power, distribution channels, procurement mechanisms and prescribing practices.

A successful market entry begins with understanding patient needs, existing treatment alternatives, product advantages and the resources required for launch.

At Sona Group, we assess these factors comprehensively, considering market opportunities, potential risks and patient needs to identify viable directions for business development.

The Value of Professional Dialogue

Beyond technologies and products, the most valuable aspect of CPHI 2026 for me was the opportunity for direct professional communication.

Face-to-face meetings help us better understand potential partners, their capabilities, expectations and willingness to work towards shared objectives.

Open discussions about scientific evidence, investment, manufacturing capacity and commercial expectations build the trust necessary for long-term cooperation.

CPHI provides an environment for strengthening existing relationships, establishing new partnerships and evaluating opportunities from different perspectives.

What I Take Away from Milan

I return from CPHI 2026 with new ideas, clearer criteria for evaluating opportunities, valuable professional connections and new agreements.

I believe the strongest positions in the pharmaceutical industry will belong to companies that successfully combine scientific evidence, manufacturing quality, regulatory readiness, reliable supply and market expertise.

The value of CPHI extends beyond the exhibition itself. It continues through product evaluation, business decisions and the development of partnerships that turn promising opportunities into practical results.

I am grateful to my colleagues, friends and partners for meaningful conversations, openness and shared expertise.

Milan has provided valuable perspectives on the industry’s future and renewed motivation to move forward. Every successful pharmaceutical project ultimately depends on people working together to bring quality products and meaningful solutions to patients.